Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 756 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Renal Disease Clear all
Completed Phase 2 Interventional Results available

Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis

NCT04622709
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Furosemide (loop diuretic) Tablets
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Carrboro, North Carolina • Pittsboro, North Carolina • Sanford, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 15, 2026, 8:29 PM EDT
Active, not recruiting No phase listed Observational

Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients

NCT04212143
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
there is no intervention
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
150 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 15, 2026, 8:29 PM EDT
Completed Not applicable Interventional

Gambro AK200 ULTRA Hemodiafiltration Study

NCT01202708
View directory record Official record
Conditions
Chronic Renal Failure
Interventions
On line hemofiafiltration, On line hemodiafiltration
Device
Lead sponsor
Vantive Health LLC
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 15, 2026, 8:29 PM EDT
Completed Not applicable Interventional Results available

Premarket Clinical Safety Assessment of the ELISIO™-HX

NCT07058909
View directory record Official record
Conditions
Renal Failure, Acute Renal Failure, Chronic Renal Failure, Chronic Kidney Diseases, End Stage Renal Disease
Interventions
ELISIO™-HX Dialyzer
Device
Lead sponsor
Nipro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 15, 2026, 8:29 PM EDT
Completed No phase listed Observational

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

NCT03413722
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 15, 2026, 8:29 PM EDT
Terminated Phase 3 Interventional

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

NCT00120328
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
SPP301
Drug
Lead sponsor
Speedel Pharma Ltd.
Industry
Eligibility
21 Years to 80 Years
Enrollment
2,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2007 · Synced Oct 15, 2026, 8:29 PM EDT
Recruiting Not applicable Interventional

Preoperative Hemodialysis Timing in Patients With End-Stage Kidney Disease: The POD-ESKD Pilot Trial

NCT07339202
View directory record Official record
Conditions
Perioperative Management, End Stage Kidney Disease (ESRD), Hemodialysis
Interventions
Same-Day Hemodialysis, No Same-Day Hemodialysis
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 15, 2026, 8:29 PM EDT
Completed Not applicable Interventional Results available

Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease

NCT02158052
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
Tacrolimus, Equine Anti-thymocyte globulin, Kidney transplant from a related donor, Bone marrow transplant from a related donor, Total body irradiation 400 centigray (200 cGy X 2)
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 15, 2026, 8:29 PM EDT
Completed Phase 1 Interventional

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

NCT01978587
View directory record Official record
Conditions
Anemia in Chronic Kidney Disease
Interventions
JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 15, 2026, 8:29 PM EDT
Completed Phase 2 Interventional Results available

Blood Pressure Lowering in Dialysis (BOLD) Trial

NCT03459807
View directory record Official record
Conditions
Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis), Chronic Kidney Diseases, Chronic Kidney Disease Stage 5
Interventions
Anti-Hypertensive medications, Dry Weight Adjustment
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 15, 2026, 8:29 PM EDT
Not listed Not applicable Interventional

A Single Arm sTudy to Evaluate the Effectiveness of EndoAVF in a Pre-dialysis Population (STEP Study)

NCT04633304
View directory record Official record
Conditions
CKD Stage 3, CKD Stage 4, CKD Stage 5
Interventions
EndoAVF System for endovascular AV fistula creation
Device
Lead sponsor
California Institute of Renal Research
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 15, 2026, 8:29 PM EDT
Terminated Phase 2Phase 3 Interventional

Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant

NCT00928811
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
basiliximab
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 15, 2026, 8:29 PM EDT
Completed Not applicable Interventional

Impact of a Personal Digital Assistant (PDA) - Based Dietary Adherence Intervention on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients

NCT00447408
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Standard hemodialysis dietary instruction, Behavioral counseling plus PDA-based self-monitoring of diet
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Oct 15, 2026, 8:29 PM EDT
Completed Not applicable Interventional

Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin

NCT00597025
View directory record Official record
Conditions
End Stage Renal Disease, Hypoalbuminemia, Malnutrition
Interventions
Protein Food Bar Intelligent Indulgence
Dietary Supplement
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 15, 2026, 8:29 PM EDT
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

NCT05836220
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Kidney Disease
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Anaheim, California • Chula Vista, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 15, 2026, 8:29 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant

NCT01619449
View directory record Official record
Conditions
Acute Kidney Injury, Liver Disease, Chronic Kidney Disease, End Stage Kidney Disease
Interventions
Renal replacement therapy
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 15, 2026, 8:29 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

NCT00293202
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Kaysen, George A., M.D., Ph.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 15, 2026, 8:29 PM EDT
Not yet recruiting Not applicable Interventional

Dry Weight Reduction Intervention Via Extra Ultrafiltration

NCT07637110
View directory record Official record
Conditions
Fluid Accumulation, Blood Pressure Management, End Stage Renal Disease (ESRD)
Interventions
Ultrafiltration
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 15, 2026, 8:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

NCT04042324
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic, Heparin
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 15, 2026, 8:29 PM EDT
Not listed Phase 2 Interventional

An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients

NCT00834301
View directory record Official record
Conditions
Hyperphosphatemia, Inflammation, Renal Disease
Interventions
Oral Multivitamin
Dietary Supplement
Lead sponsor
Nephrian
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Simi Valley, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Oct 15, 2026, 8:29 PM EDT
Recruiting Not applicable Interventional

Pivotal Study of the Velocity™ pAVF System

NCT07153939
View directory record Official record
Conditions
Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)
Interventions
Velocity Percutaneous Arteriovenous Fistula
Device
Lead sponsor
Venova Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Dothan, Alabama • Concord, California • Riverside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 8:29 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rutgers University Study of the Genetics of Kidney Disease

NCT07217535
View directory record Official record
Conditions
Kidney Disease, Kidney Disease, Chronic, Kidney Disease, End-Stage, Kidney Diseases, Kidney Diseases, Chronic, Kidney Diseases,Cystic
Interventions
Saliva sample, Health surveys
Genetic · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 15, 2026, 8:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction

NCT01708889
View directory record Official record
Conditions
Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection
Interventions
BMS-914143 (Peginterferon Lambda-1a)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 15, 2026, 8:29 PM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 15, 2026, 8:29 PM EDT